← DermaLens AI

Investor Overview · July 2026

DermaLens AI

Clinically-reviewed AI skin screening, with a real licensed doctor one tap away.

IATROVISION Technologies Private Limited CIN U62099GJ2026PTC178696 com.dermalens.ai

The Problem

Skin care in India runs into the same wall, everywhere.

Dermatologists are concentrated in a small number of cities. For most people, a skin concern means a long wait, a costly consultation, or — far more often — no consultation at all.

Geography

Specialist dermatological care is concentrated in major metros, leaving smaller towns and rural areas with little direct access.

Cost & time

An in-person specialist visit means booking, travel, and waiting — a high bar to clear for what might be a minor, easily-treated condition.

The fallback is worse

Faced with that barrier, people default to internet search or self-diagnosis — with no clinical grounding and no path to a real doctor.

The Solution

A screening you can do in a minute — with a real doctor behind it.

DermaLens AI turns a phone camera into a first opinion, and turns that first opinion into a conversation with a licensed doctor when it matters.

01

Capture

Photograph the affected area — up to four angles for a clearer read.

02

Analyze

The on-device-to-cloud AI pipeline screens the image in seconds.

03

Understand

A plain-language report explains what was found, and how confident the system is.

04

Consult

Uncertain or concerning results route straight to a licensed doctor, in-app.

The Technology

Built to know when it doesn't know.

Most consumer skin-check tools are a single model returning a confident-sounding guess. DermaLens AI is a three-stage pipeline designed around the opposite instinct: validate the input, weigh two independent opinions, and hand off to a human when certainty runs out.

Stage 1

Input validation

A CLIP-based vision model checks the photo is genuinely a skin image before any diagnosis runs — filtering out irrelevant or unusable uploads at the door.

openai/clip-vit-base-patch32

Stage 2

Ensemble diagnosis

Two independently trained classifiers score the image across ~35 dermatological conditions. Low-confidence results are returned as "uncertain," not forced into a guess.

EfficientNet-B0 + MobileNetV3-Large

Stage 3

Human escalation

Flagged or uncertain cases are pushed straight to a licensed doctor's queue in real time — closing the loop from AI to clinician inside one product.

Live doctor hand-off
~35
Dermatological conditions screened
2
Independently trained models
~10mo
Continuous R&D, Sep 2025 – present
2
Production architecture iterations

Inside the App

From photo to conversation.

01

Capture

Guided camera flow, up to 4 photos of one spot.

Live

02

Analysis

AI ensemble runs; results in seconds.

Live

03

Report

Plain-language result, confidence, and next-step guidance.

Live

04

Doctor chat

Real-time in-app text consultation with a licensed doctor.

Live

Doctor consultation today is in-app text chat with image sharing, not a scheduled video call — an intentionally lightweight, async triage model that gets a patient talking to a real clinician with no booking friction.

Business Model

Where the revenue comes from.

The product and doctor-consultation loop are live today, at no cost to the user. Monetization is the deliberate next phase — built on top of a working, in-use product rather than speculated in advance of one.

LiveDoctor chat consultationCurrently free to the patient — the core loop already works end-to-end and is the foundation every paid path below builds on.
RoadmapPremium screening & subscriptionsTiered plans for individuals — unlimited scans, history tracking, priority doctor response.
RoadmapTeleconsultation feesPaid consultation tiers once patient volume justifies compensating doctors directly per case.
RoadmapHospital & clinic partnershipsScreening-as-a-service for dermatology clinics, starting with major-city partners.
RoadmapEnterprise & API licensingLicensing the screening pipeline itself to other health platforms and providers.
RoadmapB2B SaaS for practitionersA practitioner-facing product for independent dermatologists and clinics.

Market Opportunity

Riding a shift already underway.

A large, underserved population

Skin conditions are among the most common reasons people seek medical advice, yet specialist access remains geographically concentrated across India — leaving most of the country reliant on general practitioners or no care at all.

Digital health is the direction of travel

Teleconsultation and digital-first healthcare have moved from novelty to mainstream expectation in India, mirroring the national push toward accessible digital health infrastructure.

India-built, India-first AI

DermaLens AI's models are trained and operated in-house, not resold from a foreign API — positioning it inside the country's push for sovereign, application-layer AI capability.

Land with screening, expand into care

A free, low-friction screening product is a natural top of funnel for every paid layer on the roadmap — consultations, partnerships, and licensing all sit downstream of it.

Where We Are Today

Early stage. Real product.

DermaLens AI is at Early Traction — a small team, a working product, and no external funding to date. What we have isn't a projection; it's running.

Live
Two-model AI ensemble in production
Live
Doctor chat consultation, end-to-end
2
Founding team members
Android
Live on Google Play

Clinical Review

"Every condition category and every escalation path in DermaLens AI has been shaped with a practicing physician's eye on it — not bolted on after the fact."

Dr. Rathod Samir Sunilbhai

MBBS · General Surgery Resident

The Ask

Raising to go from working product to real scale.

₹2 Cr

Seed round · 18–24 month runway

70% · Product & Tech
30% · Go-to-Market

Product & Tech — ₹1.4 Cr

  • Engineering hires
  • Medical / doctor team expansion
  • Cloud compute & infrastructure
  • Dataset collection & labeling
  • Next-generation model development

Go-to-Market — ₹60 L

  • Marketing & user acquisition
  • Dermatologist partnerships in major cities
  • Supporting infrastructure